DelveInsight’s, “Cyclin-Dependent Kinase Inhibitor Pipeline Insights 2025” report provides comprehensive insights about 45+ companies and 52+ pipeline drugs in Cyclin-Dependent Kinase Inhibitor pipeline landscape. It covers the Cyclin-Dependent Kinase Inhibitor pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cyclin-Dependent Kinase Inhibitor pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Cyclin-Dependent Kinase Inhibitor Research. Learn more about our innovative pipeline today! @ Cyclin-Dependent Kinase Inhibitor Pipeline Outlook
Key Takeaways from the Cyclin-Dependent Kinase Inhibitor Pipeline Report
- In July 2025, Eli Lilly and Company announced a Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy.
- DelveInsight’s Cyclin Dependent Kinase Inhibitor pipeline report depicts a robust space with 45+ active players working to develop 52+ pipeline therapies for Cyclin Dependent Kinase Inhibitor treatment.
- The leading Cyclin Dependent Kinase Inhibitor Companies such as G1 Therapeutics, Betta Pharmaceuticals Co Ltd, Eli Lilly and Company, Pfizer, Tiziana Life Sciences LTD, GenFleet Therapeutics, Vincerx Pharma, Syros Pharmaceuticals, BeyondBio, Kronos Bio, Qurient Co, Sumitomo Pharma, OnKure Therapeutics, Biolexis Therapeutics, InSilico Medicine, Avenzo Therapeutics and others.
- Promising Cyclin Dependent Kinase Inhibitor Therapies such as Palbociclib PD-0332991, Abemaciclib, Anastrozole, Letrozole, Vismodegib, and others.
Stay informed about the cutting-edge advancements in Cyclin-Dependent Kinase Inhibitor treatments. Download for updates and be a part of the revolution in Oncology Care @ Cyclin-Dependent Kinase Inhibitor Clinical Trials Assessment
Cyclin-Dependent Kinase Inhibitor Emerging Drugs Profile
- Abemaciclib: Eli Lilly and Company
Abemaciclib selectively inhibits CDK4 and CDK6 with low nanomolar potency. These enzymes are responsible for phosphorylating and thus deactivating the retinoblastoma protein, which plays a role in cell cycle progression from the G1 (first gap) to the S (synthesis) phase. Blocking this pathway prevents cells from progressing to the S phase, thereby inducing apoptosis (cell death). In vitro analysis using cancer cell lines shows that abemaciclib induces non‐apoptotic cell death characterized by the formation of cytoplasmic vacuoles derived from lysosomes. The drug was approved for use in combination with endocrine therapy (such as tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. Currently, the drug is in the Phase III stage of its development for the treatment of Liposarcoma and Prostate cancer.
- GFH-009: GenFleet Therapeutics/ Sellas Life Sciences Group
GFH009 is a potent and highly selective small-molecule inhibitor of CDK9 with more than 100 times selectivity over other CDK subtypes. Preclinical data have also suggested the potential anti-tumor effects of GFH009 in combination with BCL-2 inhibitors. As a potent and highly selective small molecule CDK9 inhibitor, GFH009 exhibits strong apoptosis-inducing and anti-proliferative activities in multiple human cell lines and animal models of diseases. It effectively inhibits the growth of tumor in various xenograft models and significantly improves survival of tumor bearing animals. The drug is currently in Phase II stage of Clinical trial evaluation for the treatment Hematological malignancies.
- Enitociclib: Vincerx Pharma
Enitociclib is a potent and selective CDK9 inhibitor currently in clinical development. The small molecule inhibitor targets P-TEFb/CDK9 and has shown robust pathway modulation as well as efficacy and safety in several preclinical tumor models and in early phase clinical studies. Enitociclib was identified as a top hit in small molecule inhibitor screening and exposure to Enitociclib for 96 hours against a representative panel of MM cell lines (NCI-H929, MM.1S, OPM-2, and U266B1) demonstrated significant cytotoxic activity, with IC50 values ranging from 36 to 78 nM. Vincerx Pharma is focused on Phase I/II study with the National Institutes of Health (NIH) evaluating combination of Enitociclib and Venetoclax and prednisone (VVIP) in diffuse large B-cell lymphoma (DLBCL) and peripheral T Cell Lymphoma (PTCL).
- AVZO-021: Avenzo Therapeutics Inc.
AVZO-021, also known as ARTS-021, is a promising clinical-stage drug developed by Avenzo Therapeutics, Inc. It is a highly potent and selective inhibitor of cyclin-dependent kinase 2 (CDK2), primarily aimed at treating hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer, as well as cancers with cyclin E1 (CCNE1) amplification. Currently, the drug is in the Phase I/II stage of its development for the treatment of triple negative breast cancer.
The Cyclin-Dependent Kinase Inhibitor Pipeline Report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Cyclin-Dependent Kinase Inhibitor with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cyclin-Dependent Kinase Inhibitor Treatment.
- Cyclin-Dependent Kinase Inhibitor Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Cyclin-Dependent Kinase Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cyclin-Dependent Kinase Inhibitor market.
Learn more about Cyclin-Dependent Kinase Inhibitor Drugs opportunities in our groundbreaking Cyclin-Dependent Kinase Inhibitor research and development projects @ Cyclin-Dependent Kinase Inhibitor Unmet Needs
Cyclin-Dependent Kinase Inhibitor Companies
G1 Therapeutics, Betta Pharmaceuticals Co Ltd, Eli Lilly and Company, Pfizer, Tiziana Life Sciences LTD, GenFleet Therapeutics, Vincerx Pharma, Syros Pharmaceuticals, BeyondBio, Kronos Bio, Qurient Co, Sumitomo Pharma, OnKure Therapeutics, Biolexis Therapeutics, InSilico Medicine, Avenzo Therapeutics and others.
Cyclin-Dependent Kinase Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Cyclin-Dependent Kinase Inhibitor Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
Discover the latest advancements in Cyclin-Dependent Kinase Inhibitor treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Cyclin-Dependent Kinase Inhibitor Market Drivers and Barriers, and Future Perspectives
Scope of the Cyclin-Dependent Kinase Inhibitor Pipeline Report
- Coverage- Global
- Cyclin-Dependent Kinase Inhibitor Companies- G1 Therapeutics, Betta Pharmaceuticals Co Ltd, Eli Lilly and Company, Pfizer, Tiziana Life Sciences LTD, GenFleet Therapeutics, Vincerx Pharma, Syros Pharmaceuticals, BeyondBio, Kronos Bio, Qurient Co, Sumitomo Pharma, OnKure Therapeutics, Biolexis Therapeutics, InSilico Medicine, Avenzo Therapeutics and others.
- Cyclin Dependent Kinase Inhibitor Therapies- Palbociclib PD-0332991, Abemaciclib, Anastrozole, Letrozole, Vismodegib, and others.
- Cyclin-Dependent Kinase Inhibitor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Cyclin-Dependent Kinase Inhibitor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Cyclin-Dependent Kinase Inhibitor Pipeline on our website @ Cyclin-Dependent Kinase Inhibitor Emerging Drugs and Companies
Table of Contents
- Introduction
- Executive Summary
- Cyclin-Dependent Kinase Inhibitor : Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Cyclin-Dependent Kinase Inhibitor – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Abemaciclib: Eli Lilly and Company
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- GFH-009: GenFleet Therapeutics/ Sellas Life Sciences Group
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Product Name: Company Name
- Preclinical Stage Products
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Cyclin-Dependent Kinase Inhibitor Key Companies
- Cyclin-Dependent Kinase Inhibitor Key Products
- Cyclin-Dependent Kinase Inhibitor- Unmet Needs
- Cyclin-Dependent Kinase Inhibitor- Market Drivers and Barriers
- Cyclin-Dependent Kinase Inhibitor- Future Perspectives and Conclusion
- Cyclin-Dependent Kinase Inhibitor Analyst Views
- Cyclin-Dependent Kinase Inhibitor Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cyclin-dependent-kinase-inhibitor-pipeline-insight
